Finance News – Treatment
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Shares
Ceo
Tariffs
Investors
Stock
Stock Market
Crypto Assets
Cryptocurrency
Ethereum
Price
Markets
Bse
Xrp
Etf
Stablecoin
Investment
Blockchain
Ipo
Index
Eth
Solana
Sec
Trade
Inflation
Earnings
Interest Rates
Revenue
Sensex
Token
Coinbase
Wall Street
Treasury
Nse
Nasdaq
Federal Reserve
China
Bse Sensex
Traders
Nifty
Gold
Sp 500
Investor
Tesla
Profit
Economy
Company
Mkr
Cost Cuts
Store Of Value
Corporate Restructuring Authority
Us Justice Department
Zk Rollup
Ai Deepfakes
Austin Plant
Banking Proposal
Rental Assets
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
CNBC Business • Jun 09, 2025
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck’s newly authorized RSV vaccine for infants is expected to impact the market by challenging established treatments, potentially influencing sales and market share among leadin...
Read Full Article →
MarketWatch Top Stories • May 30, 2025
Regeneron dashes Wall Street’s hopes as COPD treatment trial suffers a failure
The unsuccessful outcome of Regeneron’s advanced COPD therapy study led to a significant decline in its stock value, marking the company’s largest drop in over a decade on financia...
Read Full Article →